Article
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.
Liver international : official journal of the International Association for the Study of the Liver - 1 Nov 2015
Forns Xavier, Poordad Fred, Pedrosa Marcos, Berenguer Marina, Wedemeyer Heiner, Ferenci Peter, Shiffman Mitchell L, Fried Michael W, Lovell Sandra, Trinh Roger, Lopez-Talavera Juan Carlos, Everson Gregory
Abstract excerpt
BACKGROUND & AIMS: Thrombocytopaenia and hypoalbuminaemia are surrogate markers for portal hypertension and hepatic synthetic dysfunction respectively. Patients infected with hepatitis C virus (HCV) with these surrogates have reduced likelihood of sustained virologic response and increased risk for hepatic decompensation or death when treated with peginterferon/ribavirin plus either telaprevir or boceprevir....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.